1192739-65-3

Upstream product

• 144230-52-4 4,4-difluoropiperidine hydrochloride 
• 861151-23-7 1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid 
• 1015170-98-5 4,4-difluoropiperidine-1-sulfonamide 
• 1192739-63-1 1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxylic acid chloride 

Downstream Products

• 1192739-46-0 (5R)-(+)-N-[(4,4-difluoropiperidin-1-yl)sulfonyl]-N'-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine 
• 1192739-60-8 (5S)-(-)-N-[(4,4-difluoropiperidin-1-yl)sulfonyl]-N'-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine 

Relevant academic research and scientific papers

Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB1 receptor antagonists

The synthesis, structure-activity relationship (SAR) studies and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles are described. The target compounds 6-18 represent a novel class of potent and selective CB1 r

(5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY

This invention concerns (5R)-1,5-diaryl-4,5-dihydro-1 H-pyrazole-3-carboxamidine derivatives as cannabinoid-CB1 receptor antagonists, methods for the preparation of these compounds, novel intermediates useful for the synthesis of said dihydropy